Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) Short Interest Down 53.9% in July

Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) was the recipient of a large decline in short interest in July. As of July 31st, there was short interest totaling 37,127 shares, a decline of 53.9% from the July 15th total of 80,592 shares. Based on an average daily volume of 138,153 shares, the days-to-cover ratio is presently 0.3 days. Currently, 0.7% of the company’s stock are short sold.

Regentis Biomaterials Stock Performance

Shares of Regentis Biomaterials stock traded up $0.10 during midday trading on Friday, hitting $2.00. The company had a trading volume of 55,057 shares, compared to its average volume of 107,072. Regentis Biomaterials has a 52-week low of $1.23 and a 52-week high of $15.50. The company has a 50 day moving average of $2.97 and a 200 day moving average of $3.19.

Institutional Investors Weigh In On Regentis Biomaterials

An institutional investor recently bought a new stake in Regentis Biomaterials stock. AIGH Capital Management LLC purchased a new stake in shares of Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 300,000 shares of the company’s stock, valued at approximately $916,000. AIGH Capital Management LLC owned approximately 5.79% of Regentis Biomaterials at the end of the most recent reporting period.

About Regentis Biomaterials

Regentis Biomaterials Ltd. is a regenerative medicine company dedicated to developing tissue repair solutions which seek to restore the health. Regentis Biomaterials Ltd. is based in Herzliya, Israel.